Hemogenyx Pharmaceuticals Plc

LSE (GBp): Hemogenyx Pharmaceuticals Plc (HEMO)

Last Price

617.35

Today's Change

+80.35 (14.96%)

Day's Change

504.00 - 734.00

Trading Volume

136,443

Profile
HEMO

Exchange:  London Stock Exchange London Stock Exchange

Currency:  GBp GBp

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Vladislav Sandler Vladislav Sandler

Full Time Employees:  16 16

IPO Date:  2015-11-09 2015-11-09

CIK: 

ISIN:  GB00BYX3WZ24 GB00BYX3WZ24

CUSIP:  G4R59S104 G4R59S104

Beta:  0.62 0.62

Last Dividend:  0.00 0.00

Dcf Diff:  642.63 642.63

Dcf:  -74.63 -74.63

Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Address

60 Gracechurch Street,
London, EC3V 0HR, GB

44 79 0917 7311

http://www.hemogenyx.com

Discussions
Be the first to like this. Showing 0 of 0 comments

{uid}

{comment}

Just now

Post a Comment